Advertisement

Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer

  • Shang-Wen Chen
  • Ying-Chun Lin
  • Rui-Yun Chen
  • Te-Chun Hsieh
  • Kuo-Yang Yen
  • Ji-An Liang
  • Shih-Neng Yang
  • Yao-Ching Wang
  • Ya-Huey Chen
  • Nan-Haw Chow
  • Chia-Hung KaoEmail author
Original Article

Abstract

Background

This study examined genomic factors associated with a reduction in 18fluoro-2-deoxy-D-glucose (FDG) uptake during positron emission tomography–computed tomography (PET-CT) for definitive chemoradiotherapy (CRT) in patients with pharyngeal cancer.

Methods

The pretreatment and interim PET-CT images of 25 patients with advanced pharyngeal cancers receiving definitive CRT were prospectively evaluated. The maximum standardized uptake value (SUVmax) of the interim PET-CT and the reduction ratio of the SUVmax (SRR) between the two images were measured. Genomic data from pretreatment incisional biopsy specimens (SLC2A1, CAIX, VEGF, HIF1A, BCL2, Claudin-4, YAP1, MET, MKI67, and EGFR) were analyzed using tissue microarrays. Differences in FDG uptake and SRRs between tumors with low and high gene expression were examined using the Mann–Whitney test. Cox regression analysis was performed to examine the effects of variables on local control.

Results

The SRR of the primary tumors (SRR-P) was 0.59 ± 0.31, whereas the SRR of metastatic lymph nodes (SRR-N) was 0.54 ± 0.32. Overexpression of HIF1A was associated with a high iSUVmax of the primary tumor (P < 0.001) and neck lymph node (P = 0.04) and a low SRR-P (P = 0.02). Multivariate analysis revealed that patients who had tumors with low SRR-P or high HIF1A expression levels showed inferior local control.

Conclusion

In patients with pharyngeal cancer requiring CRT, HIF1A overexpression was positively associated with high interim SUVmax or a slow reduction in FDG uptake. Prospective trials are needed to determine whether the local control rate can be stratified using the HIF1A level as a biomarker and SRR-P.

Keywords

Head and neck cancer Positron emission tomography 18Fluoro-2-deoxy-D-glucose Chemoradiotherapy Hypoxia-inducible factor 1α 

Abbreviations

CAIX

Carbonic anhydrase 9

CRT

Chemoradiotherapy

CT

Computed tomography

FDG

18fluoro-2-deoxy-D-glucose

GLut1

Glucose transporter 1, SLCAA1 gene provides instructions for producing Glut1

HNSCC

Head and neck squamous cell carcinoma

PET-CT

Positron emission tomography and computed tomography

pSUVmax

Pretreatment maximum standardized uptake value

iSUVmax

Interim maximum standardized uptake value

SRR

SUVmax reduction ratio

VEGF

Vascular endothelial growth factor

VRR

Volume reduction ratio

Notes

Acknowledgments

Author contributions

CH Kao and SW Chen were responsible for design of the study. RY Chen, YC Lin, NH Chow, and KY Yen collected the data. RY Chen, YC Lin, and SW Chen carried out statistical analysis, interpretation of data, and drafting of the article. SN Yang, JA Liang, TC Hsieh, YC Wang, and YH Chen provided intellectual content. SW and CH Kao approved the version to be submitted for publication. SW Chen and YC Lin contributed equally. All authors read and approved the final manuscript.

Compliance with ethical standards

Funding

This study was funded in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019); China Medical University Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037); NRPB Stroke Clinical Trial Consortium (MOST 104-2325-B-039 -005); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; the Katsuzo and Kiyo Aoshima Memorial Fund, Japan; and the China Medical University under the Aim for the Top University Plan of the Ministry of Education, Taiwan, and Health and Welfare surcharge of tobacco products, China Medical University Hospital Cancer Research Center of Excellence (MOHW105-TDU-B-212-134003, Taiwan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Conflict of interest

The authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the institutional review board (IRB) of China Medical University (DMR99-IRB-010).

Informed consent

All patients provided informed consent before inclusion in this prospective study.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.CrossRefPubMedGoogle Scholar
  2. 2.
    Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Ernster JA, Sciotto CG, O’Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007;117:2115–28.CrossRefPubMedGoogle Scholar
  4. 4.
    Aukema TS, Kappers I, Olmos RA, et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med. 2010;51:1344–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004;45:56–68.PubMedGoogle Scholar
  7. 7.
    Berlangieri SU, Brizel DM, Scher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck. 1994;16:340–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Brun E, Kjellen E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127–35.CrossRefPubMedGoogle Scholar
  9. 9.
    Hentschel M, Appold S, Schreiber A, et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging. 2011;38:1203–11.CrossRefPubMedGoogle Scholar
  10. 10.
    Chen SW, Hsieh TC, Yen KY, et al. Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer. Laryngoscope. 2014;124:2732–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Goodman MD, Tarnoff M, Kain M, Slotman GJ. Interactions between outcomes and tumour response to preoperative cisplatin-sensitized radiotherapy in advanced head and neck cancer. Southern New Jersey Head and Neck Cancer Treatment Group. Am J Surg. 1997;174:527–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Wanebo H, Chougule P, Ready N, et al. Surgical resection is necessary to maximize tumour control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol. 2001;8:644–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Klimowicz AC, Bose P, Petrillo SK, Magliocco AM, Dort JC, Brockton NT. The prognostic impact of a combined carbonic anhydrase IX and Ki-67 signature in oral squamous cell carcinoma. Br J Cancer. 2013;109:1859–86.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol. 2003;179:801–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Akervall J, Nandalur S, Zhang J, et al. A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur J Cancer. 2014;50:570–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Couture C, Raybaud-Diogène H, Têtu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer. 2002;94:713–22.CrossRefPubMedGoogle Scholar
  17. 17.
    Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26:3128–37.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    McCarty KS Jr, Szabo E, Flowers JL, et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res;46:4244s-4248s.Google Scholar
  19. 19.
    Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lin SC, Liao CY, Kao CH, et al. Pretreatment maximal standardized uptake value of the primary tumor predicts outcome to radiotherapy in patients with pharyngeal cancer. J Radiat Res. 2012;53:462–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Smith TA, Zanda M, Fleming IN. Hypoxia stimulates 18F-fluorodeoxyglucose uptake in breast cancer cells via hypoxia inducible factor-1 and AMP-activated protein kinase. Nucl Med Biol. 2013;40:858–64.CrossRefPubMedGoogle Scholar
  22. 22.
    Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102:789–95.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fleming N, Manavaki R, Blower PJ, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2015;112:238–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Brown JM, William WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–47.CrossRefPubMedGoogle Scholar
  25. 25.
    Rajendran JG, Mankoff DA, O’Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by 18 F-fluoromisonidazole and 18 F-fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245–52.CrossRefPubMedGoogle Scholar
  26. 26.
    Dierckx RA, Van De Wiele C. FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging. 2008;35:1544–9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Oswald J, Treite F, Haase C, et al. Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer Lett. 2007;254:102–10.CrossRefPubMedGoogle Scholar
  28. 28.
    Minn H, Clavo AC, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol. 1996;23:941–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Stubbs M, Griffiths JR. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul. 2010;50:44–55.CrossRefPubMedGoogle Scholar
  30. 30.
    Higashi K, Ueda Y, Sakurai A, et al. Correlation of Glut-1 glucose transporter expression with 18F-FDG uptake in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2000;27:1778–85.CrossRefGoogle Scholar
  31. 31.
    Yen TC, See LC, Lai CH, et al. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45:22–9.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Shang-Wen Chen
    • 1
    • 4
    • 5
  • Ying-Chun Lin
    • 1
    • 3
  • Rui-Yun Chen
    • 2
  • Te-Chun Hsieh
    • 6
    • 7
  • Kuo-Yang Yen
    • 6
    • 7
  • Ji-An Liang
    • 1
    • 8
  • Shih-Neng Yang
    • 1
    • 7
  • Yao-Ching Wang
    • 1
  • Ya-Huey Chen
    • 9
    • 10
  • Nan-Haw Chow
    • 11
  • Chia-Hung Kao
    • 6
    • 8
    Email author
  1. 1.Department of Radiation OncologyChina Medical University HospitalTaichungTaiwan
  2. 2.Department of PathologyChina Medical University HospitalTaichungTaiwan
  3. 3.The Ph.D. Program for Cancer Biology and Drug DiscoveryChina Medical University and Academia SinicaTaichungTaiwan
  4. 4.School of MedicineChina Medical UniversityTaichungTaiwan
  5. 5.School of MedicineTaipei Medical UniversityTaipeiTaiwan
  6. 6.Department of Nuclear Medicine and PET CenterChina Medical University HospitalTaichungTaiwan
  7. 7.Department of Biomedical Imaging and Radiological ScienceChina Medical UniversityTaichungTaiwan
  8. 8.Graduate Institute of Clinical Medical Science, School of Medicine, College of MedicineChina Medical UniversityTaichungTaiwan
  9. 9.Graduate Institute of Cancer BiologyChina Medical UniversityTaichungTaiwan
  10. 10.Center for Molecular MedicineChina Medical University HospitalTaichungTaiwan
  11. 11.Department of PathologyNational Cheng Kung UniversityTainanTaiwan

Personalised recommendations